BioSpace News Archive

Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.

Hybrigenics, a leading French publicly listed bioscience firm, has today announced its re-brand to ‘ATON’ as it signifies the culmination of a transformative shift in its vision and strategy that began two years ago.

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023, in Charleston, South Carolina.

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a peer-reviewed publication of statistically significant integration of secondary and exploratory endpoint data from its previously completed Phase 2 trial of Bryostatin-1 for Alzheimer’s disease.

Immunis, Inc. is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland.

Zerion Pharma A/S (“ZERION”) today announces that the Company has elected Mr. Carl-Åke Carlsson as its new Chairman of the Board of Directors.

CEL-SCI Corporation reported it has filed a request for Scientific Advice regarding Multikine* immunotherapy for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck with the European Medicines Agency’s Scientific Advice Working Group.